missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human GTF2IRD2B (aa 515-589) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (83%), Rat (83%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-66031 (PA5-66031. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
This gene encodes a glycosylated phosphoprotein with a leucine zipper motif, two helix-loop-helix motifs (I repeats) that are similar to domains found in the TFII-I family of transcription factors, one CHARLIE8 transposable element-like sequence, and a BED zinc finger. This gene lies within a region that is deleted in Williams-Beuren syndrome. Alternatively spliced variants which encode different protein isoforms have been described; however, not all variants have been fully characterized. [provided by RefSeq, Jul 2008].
Specifications
Specifications
| Accession Number | Q6EKJ0 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 389524 |
| Name | Human GTF2IRD2B (aa 515-589) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | general transcription factor 2 I repeat domain-containing 2 beta; general transcription factor II-I repeat domain-containing protein 2 B; GTF2I repeat domain containing 2 B; GTF2I repeat domain-containing protein 2 B; GTF2IRD2 beta; GTF2IRD2B; Transcription factor GTF2IRD2-beta |
| Common Name | GTF2IRD2B |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction